|
|
|
|
Medical industry unites for disease cure
8:04 PM PDT Features Group is looking for a way to treat muscular disease that kills boys before they reach adulthood.By Brianna Bailey Some of the countrys top medical researchers arrived in Newport Beach on Thursday to help find a cure for a fatal...
|
|
|
Galapagos to build cystic fibrosis drug pipeline
access the live audio webcast R&D Update presentation todayat 13.00 CET/8 AM Mechelen, Belgium; 19 March 2010 - Galapagos NV (Euronext: GLPG) announced the decision to pursue cystic fibrosis (CF) in its strategy to deliver breakthrough medicines to patients...
|
|
|
Muscular Dystrophy - An NGO's Crusade to Help the Society
Medindia spoke to Dr.Vishwanathan, DCH, MRCP, Ph. D (Pediatric Neurology) Consultant Pediatric Neurologist and Founder President, Muscular Dystrophy Association India, a project that has crossed cultures and borders in research and facilities...
|
|
|
Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
(GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc.The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated...
|
|
|
Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
(GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc.(Nasdaq:AVII). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make...
|
|
|
Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
(GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc.The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated...
|
|
|
Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
(GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc.(Nasdaq:AVII). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make...
|
|
|
Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
(GlobeNewswire via COMTEX) ----BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc.(Nasdaq:AVII). The report includes financial, comparative and investment analyses, and pertinent industry information you need to...
|
|
|
Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
(GlobeNewswire via COMTEX) ----BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc.(Nasdaq:AVII). The report includes financial, comparative and investment analyses, and pertinent industry information you need to...
|
|
|
Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
(GlobeNewswire via COMTEX News Network) -- BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc.(Nasdaq:AVII). The report includes financial, comparative and investment analyses, and pertinent industry information you...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.(Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...
|
|
|
Grass-roots initiative raises more than $20 million to advance MDA's lifesaving mission
The spirit of St.Patrick's Day is alive and well. The Muscular Dystrophy Association today announced that, with 92 percent of some 10,000 retail locations reporting, its 2010 Shamrocks Against Dystrophy fundraiser is the most successful...
|
|
|
Competitive bidding program for durable medical equipment: Myths and realities
Medicare has been touting the merits of the "competitive" bidding program for durable, or home medical equipment and services (HME) to convince Congress that the program is good for seniors.Unfortunately, proponents have conveyed misleading information and...
|
|
|
Scientists Discover Chemical That 'Protects' Hearts of Muscular Dystrophy Patients
Heart Disease News Font Size A chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients has been discovered by University of Minnesota Medical School scientists.The chemical, which Medical School...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.(Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.(Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare
BioMarin Pharmaceutical Inc.today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in Miami on Wednesday, March 24, 2010 at 9:30 a.m.
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ BioMarin Pharmaceutical Inc.(Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...
|
|
|
Discovery Of Chemical That May Protect Hearts Of Muscular Dystrophy Patients
Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children.
|
|
|
Medical News: Discovery Of Chemical That May Protect Hearts Of Muscular Dystrophy Patients
Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children.
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results
Duchenne Muscular Dystrophy (DMD) -- AVI showed impressive levels of new dystrophin expression in DMD patients in a Phase 1 trial evaluating intramuscular injection of AVI-4658, AVI's lead drug candidate with potential to treat DMD by skipping...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results Financial Results and Corporate Update Conference Call ..
Duchenne Muscular Dystrophy (DMD) -- AVI showed impressive levels of new dystrophin expression in DMD patients in a Phase 1 trial evaluating intramuscular injection of AVI-4658, AVI's lead drug candidate with potential to treat DMD by skipping...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results
Duchenne Muscular Dystrophy (DMD) -- AVI showed impressive levels of new dystrophin expression in DMD patients in a Phase 1 trial evaluating intramuscular injection of AVI-4658, AVI's lead drug candidate with potential to treat DMD by skipping...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results
Companies mentioned in this article: AVI BioPharma, Inc.BOTHELL, WA -- (Marketwire) -- 03/16/10 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and twelve months ending December 31, 2009...
|
